Lecanemab (lecanemab)-LEQEMBI market price, drug purchase channels and patient self-pay reference instructions

Lencanezumab (LEQEMBI) is a new anti-Alzheimer's disease targeted drug for the treatment of patients with early-stage Alzheimer's disease. The drug targets and removes amyloid beta in the brain, thereby delaying disease progression and improving patients' cognitive function and daily living abilities. Although it is already on the market in China, due to limited supply, purchasing channels are relatively difficult. Patients need to consult the hospital or designated pharmacy in advance to confirm the drug inventory and purchase process.

In terms of price, it is not included in domestic medical insurance, so patients need to pay for it at their own expense. According to market information, a box of lencanezumab is relatively expensive, usually tens of thousands of yuan, and the cost is a large expense for most families. Before use, patients should rationally plan their medication plan based on their own financial situation and treatment needs to avoid economic factors affecting the continuity of long-term treatment.

The price of lencanezumab in overseas markets is also high, with the US version of the original drug selling for about more than 10,000 yuan per box. Overseas drug channels are relatively mature, and some patients can obtain them through regular overseas medical institutions or drug import channels. However, it is necessary to ensure that the channels are legal and safe, and pay attention to transportation and storage conditions to ensure drug quality and efficacy.

Overall, the purchase channels for lencanezumab in China are limited, the price is high, and patients have to bear significant out-of-pocket costs. It is recommended that patients consult doctors and pharmacies in detail before purchasing drugs to understand the drug usage and safety, and pay attention to the supply of drugs through formal channels. At the same time, you can pay attention to domestic policy adjustments and medical insurance developments to reduce the out-of-pocket burden in the future and ensure the sustainability of long-term treatment.

Reference materials:https://en.wikipedia.org/wiki/Lecanemab

xa0